Cancidas

(Caspofungin)

ApprovedSmall molecule

Cancidas is a small molecule that works as a 1,3-Beta-Glucan Synthase Inhibitor.[2] It is being used across 11 indications, with its most advanced program in Approved.[1]

Cancidas is one of 161 small molecule programs targeting Injury. It is currently in Approved.

Indications

Total Trials

Active Trials

160

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Candidiasis, InvasiveApproved

Fungal Infectious DiseaseActive, not recruiting

ShockActive, not recruiting

CandidemiaNot yet recruiting

PneumoniaActive, not recruiting

Liver FailureActive, not recruiting

AspergillosisCompleted

CandidiasisCompleted

Chronic Obstructive Pulmonary DiseaseUnknown status

ObesityCompleted

Candidiasis, InvasiveApproved

Approved

Fungal Infectious DiseaseApproved

Active, not recruiting

ShockPreclinical

Active, not recruiting

CandidemiaApproved

Not yet recruiting

PneumoniaPreclinical

Active, not recruiting

Liver FailureApproved

Active, not recruiting

AspergillosisApproved

Completed

CandidiasisApproved

Completed

Chronic Obstructive Pulmonary DiseaseApproved

Unknown status

ObesityApproved

Completed

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Cancidas

FFresenius Kabi Taiwan Ltd.

Approved

1 2

Cagrilintide

Novo Nordisk

Phase 3

9 3

Maridebart Cafraglutide

Amgen

Phase 3

7 4

Synthroid

IInstitut Jerome Lejeune

Phase 3

1 5

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 6

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

1 7

Cagrisema

Novo Nordisk

Phase 3

5 8

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

1 9

Eloralintide

Ribupatide

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Severe Infection

NCT04961593

Q1 2028

Phase 3Recruiting

Candidemia

NCT05421858

ApprovedNot yet recruiting

Candidemia

NCT07788586

Clinical

Trials by Indication[1]

Candidiasis7 trials

Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT01945281·51 enrolled

Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00099775·1,200 enrolled

Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)

Completed·MMycoses Study Group·Phase 4·NCT00520234·222 enrolled

Show 4 more trials

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

Completed· Astellas logo

Astellas·Phase 3·NCT00105144·611 enrolled

Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis

Completed· Astellas logo

Astellas·Phase 3·NCT00665639·454 enrolled

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

Completed·CCidara Therapeutics Inc.·Phase 3·NCT03667690·199 enrolled

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

Completed·CCidara Therapeutics Inc.·Phase 2·NCT02734862·207 enrolled

Tics3 trials

Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients

Completed·—·N/A·NCT02596984·50 enrolled

Pharmacokinetics of Caspofungin

Completed·MMedical University of Lublin··NCT03399032·33 enrolled

Pharmacokinetics of Caspofungin in Burn Patients

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2/3·NCT00748345·2 enrolled

Liver Transplant3 trials

Liver Transplant European Study Into the Prevention of Fungal Infection

Completed· Astellas logo

Astellas·Phase 3·NCT01058174·350 enrolled

Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients

Unknown status·AAzienda Ospedaliera di Padova·Phase 2·NCT01260974·38 enrolled

Prophylaxis With Caspofungin in High-Risk Liver Transplantation

Unknown status·GGrupo de Estudio de Infecciones en Transplantados·Phase 2·NCT00333645·70 enrolled

Candidemia3 trials

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Completed· Astellas logo

Astellas·Phase 3·NCT00413218·450 enrolled

An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis

Recruiting· Basilea Pharmaceutica logo

Basilea Pharmaceutica·Phase 3·NCT05421858·450 enrolled

A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive, Non-inferiority Trial to Investigate Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial

Not yet recruiting·OOliver Cornely, MD·Approved·NCT07788586·420 enrolled

Invasive Fungal Infection2 trials

Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates

Completed·RRadboud University Medical Center··NCT01533558·20 enrolled

Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT02510053·40 enrolled

19 more indications

Fungal Infection2 trials

Caspofungin Study for Fungal Infections in Adults in Critical Care Settings

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00095316·1,200 enrolled

Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection

Completed·PPETHEMA Foundation··NCT00388167·320 enrolled

Aspergillosis2 trials

COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis

Completed· Gilead logo

Gilead·Phase 4·NCT00334412·30 enrolled

Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis

Completed·UUniversity of Cologne·Phase 2·NCT00404092·46 enrolled

Leukemia1 trial

Prophylaxis of Fungal Invasive Infections in Leukemia

Completed·NNorthern Italy Leukemia Group·Phase 2·NCT00501098·100 enrolled

Critically Ill Patients1 trial

Optimal Dosage of Caspofungin in Critically Ill Patients

Completed·UUniversity Medical Center Groningen·Phase 4·NCT01994096·20 enrolled

First Line Therapy1 trial

Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP

Unknown status·BBin Du·Phase 4·NCT03978559·122 enrolled

Liposomal Amphotericin B1 trial

A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation

Completed·UUniversity Hospital Muenster·Phase 2·NCT00148148·75 enrolled

Severe Infection1 trial

PK/PD of Caspofungin in Children Severe Infection

Recruiting·—··NCT04961593·60 enrolled

Infection1 trial

Antimicrobial PK in Infants With Suspected or Confirmed Infection

Completed·—··NCT00491426·450 enrolled

Intensive Care Unit1 trial

Pharmacokinetics/Pharmacodynamics (PK/PD) of Caspofungin in Intensive Care Unit (ICU) Patients. An Open Observational Study for Antifungal Treatment's Optimization

Completed·—··NCT03798600·20 enrolled

Hematological Malignancy1 trial

A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT02895529·61 enrolled

MPA1 trial

Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins

Completed·—·Phase 4·NCT00839540·21 enrolled

Adolescent1 trial

A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01165320·20 enrolled

Pneumonia1 trial

Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients

Unknown status·—·N/A·NCT02603575·60 enrolled

Intravenous1 trial

Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients

Withdrawn·FF2G Biotech GmbH·Phase 1/2·NCT02856178

Safety and Efficacy1 trial

Pharmacokinetic, Safety and Efficacy of Intermittent Application of Caspofungin for Antifungal Prophylaxis

Completed·—·Phase 2·NCT01318148·25 enrolled

Liver Failure1 trial

Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure

Completed·EErasme University Hospital·Phase 4·NCT01968395·20 enrolled

Obesity1 trial

Effect of Weight and/or Obesity on Caspofungin Drug Concentrations

Completed·TTexas Tech University Health Sciences Center·Phase 4·NCT01062165·18 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease

Unknown status·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 4·NCT01499433·40 enrolled

Fever1 trial

Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin

Completed·CCttq·Phase 2·NCT03857399·32 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 26, 2001

CANCIDAS

NDA NDA021227

Dec 30, 2016

CASPOFUNGIN ACETATE

NDA NDA206110

Sources

References

[1]
ClinicalTrials.gov — 39 trial records for Caspofungin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Caspofungin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Caspofungin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA206110). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Cancidas. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Fresenius Kabi Taiwan Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: 1,3-Beta-Glucan Synthase Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFresenius Kabi Taiwan Ltd.

Patent Landscape[5]

Patent Cliff

Dec 21, 2032

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9636407Dec 21, 2032

Cancidas

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Trials by Indication[1]

Candidiasis7 trials

Tics3 trials

Liver Transplant3 trials

Candidemia3 trials

Invasive Fungal Infection2 trials

Fungal Infection2 trials

Aspergillosis2 trials

Leukemia1 trial

Critically Ill Patients1 trial

First Line Therapy1 trial

Liposomal Amphotericin B1 trial

Severe Infection1 trial

Infection1 trial

Intensive Care Unit1 trial

Hematological Malignancy1 trial

MPA1 trial

Adolescent1 trial

Pneumonia1 trial

Intravenous1 trial

Safety and Efficacy1 trial

Liver Failure1 trial

Obesity1 trial

Chronic Obstructive Pulmonary Disease1 trial

Fever1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News